Skip to main content

Table 5 Association between genotypes and median (EFS) rate in osteosarcoma patients treated with cisplatin combination

From: The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients

Genotypes

Median EFS survival rate in years

Log rank

ERCC1 118 CC

2.29

0.802

ERCC1 118 CT

1.42

ERCC1 118 TT

1.73

ERCC1 8092 CC

1.42

0.023

ERCC1 8092 CA

2.29

ERCC1 8092 AA

0.24

ERCC2 312 GG

1.42

0.147

ERCC2 312 GA

2.29

ERCC2 312 AA

1.17

ERCC2 751 AA

1.3

0.295

ERCC2 751 AC

2.8

ERCC2 751 CC

Not reached